100% Privacy Guaranteed
3 EASY STEPS
QUICK QUIZ,
QUICK ANSWERS!
Start by answering a few questions and quickly discover your eligibility. If you qualify, we’re one step closer to helping you.
SIGN ONLINE WITH NO OBLIGATIONS
If eligible, you’ll then receive your DocuSign (retainer) to help us help you. Think of it as a car key for your case. Without it, we can’t proceed. Signing isn’t a commitment, and you can opt out anytime.
PROGRESSING TOWARDS COMPENSATION
If you qualify, expect a team member to call within 24 hours. All information remains 100% confidential, and all necessary steps can be completed online!
Our partner law firms have successfully collected over $3 Billion through verdicts and settlements on behalf of injured individuals across all 50 states
100+
Trusted partners
100%
Free and Confidential
Case Review
Instant
Case Results Available 24/7
3x more likely to win your GLP-1 Weight Loss Side Effect case and secure a 2x larger settlement with the right lawyer.
Frequently Asked Questions
In December 2017, Ozempic®, developed by Novo Nordisk®, received the green light from the U.S. Food and Drug Administration (FDA) as a semaglutide-based weekly injectable for treating adults with type 2 diabetes. Besides lowering blood sugar, Ozempic® reduces the risk of heart-related issues in those with type 2 diabetes and heart disease. Although not initially authorized for weight reduction, its common side effect of weight loss has led to its off-label use for this purpose. Wegovy®, a higher dosage form of semaglutide, was later approved by the FDA in 2021 for weight management.
Ozempic® operates as a GLP-1 receptor agonist, which slows digestion by triggering the release of a hormone that supports insulin release and blocks glucose production. It mimics a naturally occurring hormone that signals fullness to the brain, thereby slowing digestion. Intended for long-term treatment, discontinuing Ozempic® can result in weight regain.
Within the realm of diabetes and weight management medications, there are other classes of GLP-1 receptor agonists, exemplified by Mounjaro® and Ozempic®. While both medications function similarly in aiding blood sugar control and potentially aiding weight loss, they are distinct. Mounjaro®, developed by Eli Lilly®, contains tirzepatide and acts as a dual GLP-1 and GIP receptor agonist, offering a broader mechanism of action compared to Ozempic®, which solely targets the GLP-1 receptor and contains semaglutide.
This litigation is still in its initial stages, and settlements for various injury categories have not been determined yet.
The primary determining factor in a potential settlement amount is the damages claimed and their calculated value. Since cases vary widely based on their individual damages, there is no standardized claim value. The estimated settlement value for cases involving gallbladder removal or wrongful death, however, is approximately $400,000 to $700,000.
Damages in an GLP-1 lawsuit may include compensation for losses related to:
- Healthcare costs
- Lost wages
- Pain and suffering
- Punitive damages
Our attorneys are currently investigating Ozempic®, Wegovy®, and Mounjaro® lawsuits involving a diagnosis of:
- Gastroparesis Stomach Paralysis
- Gastrointestinal Obstruction
- Illeus
If you have been diagnosed with any of the above conditions, or have experienced severe and prolonged vomiting, please contact us right away for a free evaluation.
Ozempic & Wegovy Lawsuit Updates
April 2024: The Judge as appointed eight firms to leadership positions on the plaintiff’s committee. 14 new cases were filed bringing the total number of pending cases to 87.
March 2024: The legal battle is just beginning. Lawyers for Novo Nordisk and Eli Lilly have officially joined the case. More people are joining the lawsuit as plaintiffs, making it bigger.
February 2024: More than 55 lawsuits claiming that Ozempic and similar drugs hurt people’s stomachs badly were grouped together in a special federal court case in Pennsylvania. The lawyers think that up to 10,000 people might join the lawsuit.
January 2024: The FDA is looking into reports that Ozempic and similar medicines for diabetes and weight loss might cause hair loss, thoughts of suicide, and problems during medical procedures where people are put to sleep. These concerns came up after several reports of these side effects were noted.
December 2023: Judge James Cain, Jr. decided not to throw out Jaclyn Bjorklund’s lawsuit against Novo Nordisk but did reject some parts of it. The rest of the lawsuit, especially about whether the company failed to warn people, will continue. Lawyers asked to bring together all Ozempic-related lawsuits in a Louisiana court.
November 2023: In Canada, a lawsuit was started claiming that Novo Nordisk didn’t warn people enough about the risk of a serious stomach problem called gastroparesis from taking Ozempic. This lawsuit is like others happening in different places.
September 2023: The FDA added warnings to Ozempic’s label about possible serious stomach problems and blockages.
August 2023: Jaclyn Bjorklund filed one of the first lawsuits against Ozempic and Mounjaro for causing gastroparesis, a serious stomach issue. Legal papers were sent to Novo Nordisk and Eli Lilly in early August. In November, Novo Nordisk tried to get the lawsuit dismissed.
July 2023: The ASHP, a big group of pharmacy workers, said that Novo Nordisk was running low on Ozempic and Wegovy, another similar medicine, because a lot of people want them.
August 2022: Courts decided to handle seven lawsuits against Novo Nordisk together because they were all about patent rights related to making generic versions of Ozempic. Also, after a study suggested Ozempic could increase the risk of gallbladder problems, lawyers started to take cases about that issue.